Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Prophylactic/therapeutic agent for cancer

A therapeutic agent, cancer technology, applied in pill delivery, medical preparations containing active ingredients, animal/human proteins, etc., can solve the problem of undiscovered androgen-independent prostate cancer, etc.

Inactive Publication Date: 2012-01-25
TAKEDA PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no drug has been found to be effective against androgen-independent prostate cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Prophylactic/therapeutic agent for cancer
  • Prophylactic/therapeutic agent for cancer
  • Prophylactic/therapeutic agent for cancer

Examples

Experimental program
Comparison scheme
Effect test

specific example

[2886] Specific examples are: (1) EGF (epidermal growth factor) or substances having substantially the same activity as EGF [for example, EGF, nerve growth factor (HER ligand), etc.], (2) insulin or substances having substantially the same activity as insulin A substance with the same activity [for example, insulin, IGF (insulin-like growth factor)-1, IGF-2, etc.], (3) FGF (fibroblast growth factor) or a substance with substantially the same activity as FGF [for example, Acidic FGF, basic FGF, KGF (keratinocyte growth factor), FGF-10, etc.], (4) other cell growth factors [eg, CSF (colony stimulating factor), EPO (erythropoietin), IL-2 (interleukin-2), NGF (nerve growth factor), PDGF (platelet-derived growth factor), TGFβ (trans-transforming growth factor-β), HGF (hepatocyte growth factor), VEGF (vascular endothelial growth factor), etc.

[2887] As long as it can be combined with the above-mentioned cell growth factor, the "receptor of cell growth factor" can be any receptor,...

Embodiment

[2949] The present invention will be further illustrated by the following preparation examples and test examples. The present invention is not limited to the above examples, and various changes and corrections are included in the present invention as long as they do not deviate from the spirit and scope of the present invention.

[2950] In the following examples, "room temperature" generally refers to about 10°C to about 35°C. The symbol "%" used hereinafter means mol / mol% with respect to yield, vol% with respect to the solvent used in chromatography, and elsewhere with wt%. In proton NMR spectra, results for broad and undetermined protons such as OH and NH are not mentioned in the data.

[2951] Abbreviated description

[2952] 10Ψ, CSNH: C-terminal -CONH at the 10-position 2 By-CSNH 2 replace.

[2953] 1Ψ2,CH 2 NH: The -CONH- bond between the 1- and 2-positions is replaced by -CH 2 NH-bond substitution.

[2954] 2Ψ3,CH 2 NH: -CONH-bond between 2- and 3-positions re...

preparation example 1

[3195] (1) Compound No.550 10.0mg

[3196] (2) Lactose 60.0mg

[3197] (3) Corn starch 35.0mg

[3198] (4) Gelatin 3.0mg

[3199] (5) Magnesium stearate 2.0mg

[3200] Using 0.03 ml of 10% aqueous gelatin solution (containing 3.0 mg gelatin), a mixture containing 10.0 mg of Compound No. 550, 60.0 mg of lactose and 35.0 mg of corn starch was granulated through a sieve with a 1 mm mesh at 40° C. Dry and pass through a sieve again. The prepared granules were mixed with 2.0 mg of magnesium stearate and compressed into tablets. The resulting plain tablets were sugar coated with an aqueous suspension of sucrose, titanium dioxide, talc and gum arabic. The obtained coated tablets were then polished with beeswax to obtain coated tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A prophylactic / therapeutic agent for androgen-independent cancer is provided. A prophylactic / therapeutic agent for androgen-independent cancer includes a metastin derivative, and is particularly useful as a prophylactic / therapeutic agent for androgen-independent cancer, in particular, androgen-independent prostate cancer.

Description

technical field [0001] The present invention relates to a preventive / therapeutic agent for androgen-independent prostate cancer. Background technique [0002] Prostate cancer is a type of cancer that occurs more frequently in older men. Androgens are closely related to the development of the disease. Therefore, tumor growth can be suppressed by inhibiting the production of androgen or its function. Modes of treatment by inhibition of androgen production or its function include surgical castration with orchiectomy, chemical castration with GnRH agonists, blockade of androgen signaling with androgen antagonists, suppression of androgen activation with estrogen drugs produce. [0003] Known agents for the treatment of prostate cancer include: diethylstilbestrol, chlormadinone acetate, cyproterone acetate, goserelin acetate, buserelin acetate, leuprolide acetate, ganirelix, flutamide , bicalutamide, nilutamide, finasteride, dexamethasone, prednisolone, ketoconazole and lyase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K38/00A61K38/08A61K38/17A61P35/00
CPCA61K9/2018A61K9/0004A61K9/0019A61K38/08A61K38/1709C07K14/4703A61K31/131C07K14/4748A61K9/1647A61P13/08A61P35/00A61P5/26
Inventor 松井久典
Owner TAKEDA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com